SINEMET
**DRUG:** SINEMET (CARBIDOPA/LEVODOPA) **SUMMARY:** SINEMET is a combination of carbidopa and levodopa indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism resulting from carbon monoxide or manganese intoxication. The inclusion of carbidopa, a peripheral decarboxylase inhibitor, prevents the premature breakdown of levodopa. This allows for a higher concentration of levodopa to reach the brain, enabling lower overall dosing and improving clinical response in patients, including those who may have responded poorly to levodopa monotherapy. Furthermore, carbidopa significantly reduces peripheral side effects such as nausea and vomiting and permits more rapid dose titration.
How SINEMET Works
Parkinson's disease symptoms are characterized by the depletion of dopamine in the corpus striatum. Because exogenous dopamine cannot cross the blood-brain barrier, it is ineffective as a direct treatment. Levodopa, the metabolic precursor of dopamine, is able to cross the blood-brain barrier, where it is converted into dopamine to alleviate motor symptoms. Carbidopa functions as an aromatic amino acid decarboxylase inhibitor, specifically blocking the peripheral conversion of levodopa to dopamine before it reaches the central nervous system. This mechanism increases the bioavailability of levodopa for the brain without carbidopa exerting a primary effect on the nervous system itself.
Details
- Status
- Prescription
- First Approved
- 1975-05-02
- Routes
- ORAL
- Dosage Forms
- TABLET
SINEMET Approval History
What SINEMET Treats
7 indicationsSINEMET is approved for 7 conditions since its original approval in 1975. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Parkinson's Disease
- Post-Encephalitic Parkinsonism
- Parkinsonism
- Carbon Monoxide Intoxication
- Manganese Intoxication
- Nausea
- Vomiting
Drugs Similar to SINEMET
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
SINEMET FDA Label Details
ProIndications & Usage
FDA Label (PDF)SINEMET is indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on SINEMET. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic e...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.